通过使用基因组数据对阿尔茨海默病亚型进行分类和基于深度学习的预测
Daichi Shigemizu1,2, Shintaro Akiyama3, Mutsumi Suganuma3
1Medical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan. daichi@ncgg.go.jp.
Translational psychiatry
|June 29, 2023
概括
研究人员确定了晚发性阿尔茨海默病 (LOAD) 的两种不同的遗传亚型. 一个亚型与免疫基因有关,而另一个与功能障碍有关,这表明新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 老年学是指老年学的学科.
背景情况:
- 晚期阿尔茨海默病 (LOAD) 是老年人常见的多因素神经退行性疾病.
- 负载呈现异质症状,其遗传基础,特别是亚型,仍然不完全理解.
- 之前的全基因组关联研究 (GWAS) 确定了LOAD风险因素,但没有区分LOAD亚型.
研究的目的:
- 使用日本GWAS数据调查LOAD亚型的遗传结构.
- 识别与不同LOAD患者组相关的独特遗传特征.
- 探索已识别的遗传因素和生理标记之间的潜在联系.
主要方法:
- 对来自发现队列 (1947 LOAD患者,2192对照) 和验证队列 (847 LOAD患者,2298对照) 的日本GWAS数据的分析.
- 鉴定与不同LOAD患者组相关的遗传风险因素和基因组.
- 遗传发现与常规血液检测标记物 (白蛋白,血红蛋白) 之间的相关性分析.
- 开发用于预测LOAD亚型的深度神经网络模型.
主要成果:
- 确定了两个不同的LOAD遗传亚型.
- 第1亚型的特征是主要的LOAD风险基因 (APOC1,APOC1P1) 和与免疫相关的基因 (RELB,CBLC).
- 亚型2的特征是与脏疾病相关的基因 (AXDND1,FBP1,MIR2278).
- 分析表明,功能受损与LOAD病变发生之间存在潜在联系.
- 一个深度神经网络模型为LOAD亚型实现了0.694 (发现) 和0.687 (验证) 的预测准确度.
结论:
- LOAD表现出不同的遗传亚型,具有潜在不同的致病机制.
- 与脏疾病相关的遗传因素可能在LOAD病例的一个子集中起作用.
- 这些发现为LOAD病原体提供了新的见解,并为特定亚型的诊断和治疗提出了途径.
相关概念视频
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220


